NeuroDerm to Announce Updated Topline Results of Phase II Study of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa for the Treatment of Parkinson’s Disease at the 67th Annual Meeting of the American Academy of Neurology
NeuroDerm to Announce Updated Topline Results of Phase II Study of ND0612L at the 67th Annual Meeting of the American Academy of Neurology